Generic Name: azacitidine
Drug Class: Chemotherapy Medications
Approval Status: Approved
Generic Version Available: No
Onureg (azacitidine) is a nucleoside analog approved for continued treatment of people with acute myeloid leukemia who achieved complete remission following induction chemotherapy.
Onureg is a cytidine nucleoside analog that inhibits cancer cell multiplication. In the QUAZAR trial, which enrolled people who achieved complete remission after intensive induction chemotherapy but were unable to finish curative therapy, patients treated with Onureg had an overall survival of 24.7 months compared with 14.8 months in the placebo arm. It was first approved in September 2020.
Onureg is a tablet taken once daily for two weeks in each monthly cycle. Onureg tablets should not be substituted for injectable or intravenous formulations of azacitidine (sold as Vidaza).
Common adverse reactions include nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, weakness, decreased appetite, neutropenia, dizziness, joint pain and pain in the extremities. More serious adverse events include depletion of blood cells, which can lead to infections. Onureg can cause fetal harm if used during pregnancy.
For More Info: https://www.onuregpro.com/
Patient Assistance Program Info: https://www.bmsaccesssupport.bmscustomerconnect.com/patient
Last Reviewed: September 4, 2020